ChemoCentryx Inc. (NASDAQ:CCXI) finished Wednesday with an addition of $0.91 to close at $36.91, an upside of 2.53 percent. An average of 41,728,180 shares of common stock have been traded in the last five days. There was a gain of $18.32 in the past week. The last 20 days have seen an average of 12,108,529 shares traded, while the 50-day average volume stands at 5,570,338.
CCXI stock has increased by 135.55% in the last month. The company shares reached their 1-month lowest point of $15.35 on 09/14/21. With the stock rallying to its 52-week high on 02/09/21, shares of the company touched a low of $9.53 and a high of $70.29 in 52 weeks. In spite of this, the price is down -47.49% from the 52-week high.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
2 days have passed since ChemoCentryx Inc. (CCXI) last reported insider trading activity. Vifor (International) Ltd, who is 10% Owner, most recently acquired $4,000,000 shares at $39.43 per share on Oct 12. In this transaction, the insider spent $157,720,000. Director, Tyree James L, disposed of 2,454 shares at a price of $9.76 on May 21. The insider now owns more than $23,956 worth of shares. Prior to that, Director Parker Geoffrey M. went on to Sale 30,000 shares at $56.38 each on Mar 05. An amount of $1,691,468 was transacted.
ChemoCentryx Inc. (CCXI) has a trailing price-to-earnings (P/E) ratio of 34.65 for the broader industry and 32.30 for the sector. In the last five years, ChemoCentryx Inc.’s PE ratio has ranged between 50.56 and 16.39. The stock’s beta is 1.41. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 60.95, the price-to-book (PB) ratio at 7.80.
The quick ratio of ChemoCentryx Inc. for the three months ended June 29 was 5.70, and the current ratio was 5.70, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.04 and a total debt to equity ratio of 0.07 for the quarter ending June 29. ChemoCentryx Inc.’s EBITDA margin for the year ending June 29 is -80.77%. Its gross profit as reported stood at $120.07 million compared to revenue of $64.89 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, ChemoCentryx Inc.’s return on assets was -24.30%, compared to -17.5% over the last five years. In the past year, the return on investment has been -13.50%, and the 5-year average is -44.9%. Meanwhile, the return on equity (ROE) for the past 12 months has been -33.20% and the 5-year average holds at -56.1%. For the broader industry, ROE averaged -68.79 over the past year.
For the three-month period that ended June 29, ChemoCentryx Inc. had $235.4 million in cash. The analyst consensus anticipated ChemoCentryx Inc.’s latest quarter earnings to come in at -$0.54 per share, but it turned out to be -$0.56, a -3.70% surprise. For the quarter, EBITDA amounted to -$37.16 million. Shareholders own equity worth $69.9 million.
From a technical analysis perspective, let’s take a brief look at ChemoCentryx Inc. (CCXI) price momentum. RSI 9-day as of the close on 13 October was 77.46%, suggesting the stock is Overbought, with historical volatility in this time frame at 332.95%.
As of today, CCXI’s price is $34.28 +98.55% or $18.32 from its 5-day moving average. CCXI is currently trading +130.98% higher than its 20-day SMA and +284.88% higher than its 100-day SMA. However, the stock’s current price level is +144.28% above the SMA50 and -39.04% below the SMA200.
The stochastic %K and %D were 82.85% and 84.28%, respectively, and the average true range (ATR) was 4.16. With the 14-day stochastic at 79.34% and the average true range at 3.24, the RSI (14) stands at 77.43%. The stock has reached 10.48 on the 9-day MACD Oscillator while the 14-day reading was at 13.53.
SVB Leerink upgraded ChemoCentryx Inc. (NASDAQ: CCXI) to a an Outperform rating in its most recent analyst report. Previously, the stock was rated as a a Mkt perform.The consensus rating for ChemoCentryx Inc. (CCXI) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell CCXI, while 1 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 7 others rate it as a “buy”.
What is CCXI’s price target for the next 12 months?
Analysts predict a range of price targets between $38.00 and $107.00, with a median target of $64.00. Taking a look at these predictions, the average price target given by analysts for ChemoCentryx Inc. (CCXI) stock is $70.88.